Clinical evaluation of efficacy and safety of CLARITH Tablets 200 mg (800mg/day) against community acquired bacterial pneumonia and mycoplasma pneumonia. - Clinical evaluation of CLARITH Tablets 200 mg (800mg/day) against community acquired bacterial pneumonia and mycoplasma pneumonia.

Organization of Clinical Trials for Respiratory and Infectious Disease0 个研究点目标入组 24 人开始时间: 2012年10月29日最近更新: 2023年10月17日

适应症

试验速览

暂无简介。

•1)Patients with known hypersensitivity to clarithromycin or any other component of the product. 2)Patients receiving treatment with pimozide, ergotamine(or its derivatives), or tadalafil/ADCIRCA. 3)Patients under 20 years old. 4)Patients with hypersensitivity to any other antibiotics. 5)Patients with hepatic dysfunction, renal impairment, cardiac disorder, or other severe complication which inadequate this study. 6)Women known pregnant, lactation or suspected to be pregnant. 7)Patients who are regarded as inadequate subject by physician in charge (*) *Posible to enter the patients who treat low-dose long-time macrolides therapy(200mg) when increase the dosage(800mg). *Posible to enter the patients who previously treat 400mg of clarithromycin if increase the dosage(800mg).

发起方

Organization of Clinical Trials for Respiratory and Infectious Disease